Pharma BD Deal Intelligence
Bayer's first pharmaceutical purchase since August 2021 ends a multi-year M&A drought: $300 million upfront for Perfuse's PER-001 shores up an Eylea franchise facing biosimilar erosion, though no expected close date has been disclosed.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Bayer agreed to acquire Perfuse Therapeutics for up to $2.45 billion, comprising $300 million upfront and up to $2.15 billion in development, regulatory, and…
Bayer Secures PER-001 Through Perfuse Deal. The acquisition gives Bayer global rights to a Phase 2 endothelin receptor antagonist intravitreal implant…
Pharma M&A Roundup: Bayer to Acquire Perfuse Therapeutics for up to $2.45 billion, gaining global rights to PER-001, a Phase 2 small-molecule endothelin…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Bayer agreed to fully acquire Perfuse Therapeutics for up to $2.45B ($300M upfront + up to $2.15B in development, regulatory, and commercial milestones), announced May 6, 2026. Bayer obtains global rights to PER-001, a first-in-class small-molecule endothelin receptor antagonist delivered as a sustained-release intravitreal implant (single-use 25-gauge applicator, dosed roughly every six months) that improves retinal blood flow and reduces ocular ischemia. PER-001 completed Phase 2a trials in glaucoma and diabetic retinopathy (positive 24-week data reported June 2025) with pivotal trials planned; future expansion into dry age-related macular degeneration is contemplated. The transaction is subject to antitrust clearance and Perfuse stockholder approval; no expected close date was disclosed. The deal complements Bayer's ophthalmology franchise anchored by Eylea and marks Bayer's return to M&A after a multi-year drought.
4.2M US cases/yr · $3.6B 2024 US diabetic retinopathy market (~37.8% of $9.48B global) · 7,700,000 US adults 40+ with diabetic retinopathy
Open-angle glaucoma and diabetic retinopathy are leading causes of irreversible vision loss in adults, both characterized by retinal ischemia and progressive neuroretinal cell death. Glaucoma affects ~4.2M Americans (~80% open-angle) and diabetic retinopathy affects ~7.7M US adults 40+. Standard care for glaucoma reduces intraocular pressure but does not address vascular dysfunction; anti-VEGF therapy (Eylea, Lucentis) dominates DR but loses patients to biosimilar competition. Endothelin pathway blockade offers a vascular-neuroprotective mechanism orthogonal to existing options.
Glaucoma therapeutics is dominated by IOP-lowering prostaglandin analogs (Xalatan generics, Lumigan, Vyzulta) and rho-kinase inhibitors (Rhopressa); DR is dominated by anti-VEGF (Regeneron/Bayer Eylea, Roche Vabysmo, Lucentis biosimilars). PER-001 differentiates as the first neuroprotective small-molecule endothelin antagonist via a sustained-release intravitreal implant. Bayer's strategic logic: replace declining Eylea franchise (biosimilar erosion) and build a neuroprotective adjacency. Competing endothelin-pathway approaches are largely systemic and not ophthalmology-optimized.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Perfuse Therapeutics, Inc. (this deal) | 2026 | $2.5B | — |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2026 deals · Bayer AG deals · Metabolic deals